Abstract
Background & Aims Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver pathology in western countries, with serious public health consequences. Efforts to identify causal genes for NAFLD have been hampered by the relative paucity of human data from gold-standard magnetic resonance quantification of hepatic fat. To overcome insufficient sample size, genome-wide association studies using NAFLD surrogate phenotypes have been used, but only a small number of loci have been identified to date. In this study, we combined GWAS of NAFLD composite surrogate phenotypes with genetic colocalization studies followed by functional in vitro screens to identify bona fide causal genes for NAFLD.
Approach & Results We used the UK Biobank to explore the associations of our novel NAFLD score, and genetic colocalization to prioritize putative causal genes for in vitro validation. We created a functional genomic framework to study NAFLD genes in vitro using CRISPRi. Our data identify VKORC1, TNKS, LYPLAL1 and GPAM as regulators of lipid accumulation in hepatocytes and suggest the involvement of VKORC1 in the lipid storage related to the development of NAFLD.
Conclusions Complementary genetic and genomic approaches are useful for the identification of NAFLD genes. Our data supports VKORC1 as a bona fide NAFLD gene. We have established a functional genomic framework to study at scale putative novel NAFLD genes from human genetic association studies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
PSG is supported by the Swedish Research Council (Vetenskapsradet), grant number 2018-06580 and the Swedish Heart-Lung Foundation grant number 20170221. JMJ is funded by grants from the Novo Nordisk Foundation and the Stanford Bio-X Program (NNF17OC0025806). JWK is supported by the NIH through grants P30 DK116074 (to the Stanford Diabetes Research Center), R01 DK116750, R01 DK120565, R01 DK106236; and by the American Diabetes Association through grant 1-19-JDF-108. AR is supported by the Finnish Foundation for Cardiovascular Research, Diabetes Research Foundation, Emil Aaltonen Foundation, Ida Montins Foundation, Biomedicum Helsinki Foundation, Orion Research Foundation and the Finnish Medical Foundation. The ASAP study was supported by the Swedish Research Council grant number 2020-01442, the Swedish Heart‐Lung Foundation grant number 20180451 and a donation by Mr. Fredrik Lundberg. PA is supported by MCIU/AEI/FEDER, UE (PID2021-124425OB-I00) and Basque Government, Department of Education (IT1476-2).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The UKB study was approved by the Northwest Multi-Center Research Ethics Committee and all participants provided written informed consent to participate.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Financial Support: PSG is supported by the Swedish Research Council (Vetenskapsrådet), grant number 2018-06580 and the Swedish Heart-Lung Foundation grant number 20170221. JMJ is funded by grants from the Novo Nordisk Foundation and the Stanford Bio-X Program (NNF17OC0025806). JWK is supported by the NIH through grants: P30 DK116074 (to the Stanford Diabetes Research Center), R01 DK116750, R01 DK120565, R01 DK106236; and by the American Diabetes Association through grant 1-19-JDF-108. AR is supported by the Finnish Foundation for Cardiovascular Research, Diabetes Research Foundation, Emil Aaltonen Foundation, Ida Montin’s Foundation, Biomedicum Helsinki Foundation, Orion Research Foundation and the Finnish Medical Foundation. The ASAP study was supported by the Swedish Research Council grant number 2020-01442, the Swedish Heart-Lung Foundation grant number 20180451 and a donation by Mr. Fredrik Lundberg. PA is supported by MCIU/AEI/FEDER, UE (PID2021-124425OB-I00) and Basque Government, Department of Education (IT1476-2).
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
